美国HIV成人癌症发病率与趋势
2015至2019年较2010至2014年,弥漫大B细胞淋巴瘤、卡波西肉瘤、霍奇金淋巴瘤、肺癌和肝癌发病率分别下降23%、24%、25%、17%和25%。2015至2019年多种癌症风险仍显著升高,且多数癌症的标准化发病比随年龄增长显著下降。
要点
- 2015至2019年较2010至2014年,弥漫大B细胞淋巴瘤发病率下降23%(IRR 0.77,95%CI 0.70-0.84)。
- 同期卡波西肉瘤下降24%(IRR 0.76,95%CI 0.69-0.84),霍奇金淋巴瘤下降25%(IRR 0.75,95%CI 0.65-0.86)。
- 同期肺癌下降17%(IRR 0.83,95%CI 0.77-0.90),肝癌下降25%(IRR 0.75,95%CI 0.67-0.84)。
核心结论
- 在这项队列研究中,HIV感染者癌症发病率和相对风险显著下降,表明HIV治疗和癌症预防持续进展。
- 这些估计可能为HIV感染者进入癌症风险更高年龄时的预防和早期检测优先事项提供见解。
研究设计与样本
- 这项基于人群的队列研究使用2001至2019年美国12个州、华盛顿特区和波多黎各的数据。
- 分析纳入HIV/AIDS癌症匹配研究中的HIV感染者和一般人群,分析于2023年10月至2024年12月进行。
主要发现
- 2015至2019年较2010至2014年,弥漫大B细胞淋巴瘤发病率下降23%(IRR 0.77,95%CI 0.70-0.84)。
- 同期卡波西肉瘤下降24%(IRR 0.76,95%CI 0.69-0.84),霍奇金淋巴瘤下降25%(IRR 0.75,95%CI 0.65-0.86)。
- 同期肺癌下降17%(IRR 0.83,95%CI 0.77-0.90),肝癌下降25%(IRR 0.75,95%CI 0.67-0.84)。
- 70至84岁HIV感染者中,发病率最高为前列腺癌(448.01;95%CI 404.26-495.20)、肺癌(269.79;95%CI 240.86-301.24)、女性乳腺癌(202.29;95%CI 155.79-258.32)、肝癌(82.82;95%CI 67.16-101.03)和结肠癌(107.57;95%CI 89.61-128.08),超过弥漫大B细胞淋巴瘤(41.83;95%CI 30.95-55.31)和卡波西肉瘤(15.37;95%CI 9.11-24.29)。
- 2015至2019年,HIV感染者多种癌症风险仍显著升高,包括卡波西肉瘤(SIR 213.87;95%CI 198.81-229.73)、霍奇金淋巴瘤(SIR 6.29;95%CI 5.68-6.94)、弥漫大B细胞淋巴瘤(SIR 5.25;95%CI 5.25-6.01)、肛门癌(SIR 17.07;95%CI 16.01-18.17)、外阴癌(SIR 11.40;95%CI 9.60-13.44)、肝癌(SIR 1.89;95%CI 1.74-2.05)和肺癌(SIR 1.59;95%CI 1.51-1.68);对于几乎所有这些癌症,SIR随年龄增长显著下降。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: People with HIV are living longer due to improvements in antiretroviral therapy over the last 2 decades. Current age-specific estimates of cancer risk among people with HIV may inform cancer prevention and clinical guidelines for this population. OBJECTIVE: To estimate cancer incidence rates (IRs) using a population-based linkage of HIV and cancer registries. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used data from 12 US states, Washington, DC, and Puerto Rico from 2001 to 2019. People with HIV and the general population in the HIV/AIDS Cancer Match Study were included in the analysis, which occurred between October 2023 and December 2024. MAIN OUTCOMES AND MEASURES: Age-standardized IRs (per 100 000 person-years) were calculated across calendar periods (2001 to 2004, 2005 to 2009, 2010 to 2014, and 2015 to 2019) and incidence rate ratios (IRRs) across calendar periods using adjusted Poisson regression. Standardized incidence ratios (SIRs) were estimated for 2010 to 2014 and 2015 to 2019, and age group-specific cancer incidence and SIRs were estimated for 2010 to 2019. RESULTS: The analysis included 7.2 million person-years among 847 107 people with HIV (5.3 million person-years among males [73%]). Comparing years 2015 to 2019 to years 2010 to 2014, incidence of diffuse large B-cell lymphoma (DLBCL) decreased 23% (IRR, 0.77; 95% CI, 0.70-0.84), Kaposi sarcoma (KS) decreased 24% (IRR, 0.76; 95% CI, 0.69-0.84), Hodgkin lymphoma decreased 25% (IRR, 0.75; 95% CI, 0.65-0.86), and cancers of the lung decreased 17% (IRR, 0.83; 95% CI, 0.77-0.90) and liver decreased 25% (IRR, 0.75; 95% CI, 0.67-0.84). Among people with HIV aged 70 to 84 years, IRs were highest for cancers of the prostate (448.01; 95% CI, 404.26-495.20), lung (269.79; 95% CI, 240.86-301.24), female breast (202.29; 95% CI, 155.79-258.32), liver (82.82; 95% CI, 67.16-101.03), and colon (107.57; 95% CI, 89.61-128.08), exceeding the IRs for DLBCL (41.83; 95% CI, 30.95-55.31) and KS (15.37; 95% CI, 9.11-24.29). From 2015 to 2019, risk remained significantly elevated in people with HIV for several cancer types, including KS (SIR, 213.87; 95% CI, 198.81-229.73), Hodgkin lymphoma (SIR, 6.29; 95% CI, 5.68-6.94), DLBCL (SIR, 5.25; 95% CI, 5.25-6.01), cancers of the anus (SIR, 17.07; 95% CI, 16.01-18.17), vulva (SIR, 11.40; 95% CI, 9.60-13.44), liver (SIR, 1.89; 95% CI, 1.74-2.05), and lung (SIR, 1.59; 95% CI, 1.51-1.68). For nearly all these cancers, SIRs significantly declined with increasing age. CONCLUSIONS AND RELEVANCE: In this cohort study, significant declines in the incidence and relative risk for cancers among people with HIV demonstrate continued progress in HIV treatment and cancer prevention. These estimates may provide insight into the priorities for prevention and early detection of cancer as the population of people with HIV enters ages with greater risk for cancer.
引用
- Haas CB, McGee-Avila JK, Luo Q, et al. Cancer Incidence and Trends in US Adults With HIV. JAMA Oncol. 2025. PMID: 40504560. doi:10.1001/jamaoncol.2025.1589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。